What is Synedgen?
Synedgen is a specialized biopharmaceutical firm dedicated to the development of first-in-class therapeutics designed to restore mucosal barrier integrity. The company's core innovation lies in its ability to repair gastrointestinal mucosal injury, thereby mitigating inflammation and restoring essential physiological functions. Their lead asset, MIIST305, represents a significant advancement in oral therapeutic delivery, leveraging robust intellectual property and scalable Good Manufacturing Practice (GMP) production standards.
Operating at the intersection of regenerative medicine and gastroenterology, Synedgen provides a sophisticated solution for patients suffering from chronic GI conditions. By focusing on targeted molecular mechanisms, the firm distinguishes itself from traditional pharmaceutical approaches, offering a more precise and effective modality for long-term patient care and disease management.
How much funding has Synedgen raised?
Synedgen has raised a total of $18.7M across 6 funding rounds:
Private Equity
$607K
Private Equity
$3.5M
Unspecified
$6M
Debt
$3M
Debt
$3M
Private Equity
$2.6M
Private Equity (2014): $607K, investors not publicly disclosed
Private Equity (2015): $3.5M, investors not publicly disclosed
Unspecified (2016): $6M, investors not publicly disclosed
Debt (2016): $3M featuring Undisclosed
Debt (2017): $3M backed by Undisclosed
Private Equity (2020): $2.6M, investors not publicly disclosed
Key Investors in Synedgen
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Synedgen?
With the recent influx of capital, Synedgen is well-positioned to transition its lead assets through advanced clinical trials and regulatory review. The strategic focus will likely center on scaling GMP manufacturing to meet anticipated market demand while simultaneously strengthening its intellectual property portfolio to maintain a competitive edge in the biotech sector.
Future growth initiatives will likely involve expanding the application of their mucosal barrier technology to other therapeutic areas, potentially diversifying their pipeline beyond gastrointestinal diseases. As the company moves toward commercialization, the emphasis will remain on demonstrating clinical efficacy and establishing partnerships with larger pharmaceutical entities to facilitate global distribution and patient access.
